Will NovoCure Limited (NVCR) Run Out of Steam Soon?

The stock of NovoCure Limited (NASDAQ:NVCR) reached all time high today, Aug, 15 and still has $95.01 target or 5.00 % above today’s $90.49 share price. This indicates more upside for the $8.88B company. This technical setup was reported by Barchart.com. If the $95.01 PT is reached, the company will be worth $444.20 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 4.77% or $4.12 during the last trading session, reaching $90.49. About 757,016 shares traded. NovoCure Limited (NASDAQ:NVCR) has risen 149.16% since August 15, 2018 and is uptrending. It has outperformed by 149.16% the S&P500.

Analysts await NovoCure Limited (NASDAQ:NVCR) to report earnings on October, 24. They expect $-0.02 earnings per share, up 84.62 % or $0.11 from last year’s $-0.13 per share. After $-0.01 actual earnings per share reported by NovoCure Limited for the previous quarter, Wall Street now forecasts 100.00 % negative EPS growth.

NovoCure Limited (NASDAQ:NVCR) Ratings Coverage

Among 3 analysts covering NovoCure (NASDAQ:NVCR), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. NovoCure has $9100 highest and $50 lowest target. $73.75’s average target is -18.50% below currents $90.49 stock price. NovoCure had 9 analyst reports since March 20, 2019 according to SRatingsIntel. JP Morgan downgraded the stock to “Neutral” rating in Friday, July 26 report. Mizuho maintained the shares of NVCR in report on Friday, July 26 with “Buy” rating.

More notable recent NovoCure Limited (NASDAQ:NVCR) news were published by: Fool.com which released: “Here’s Why Novocure Is Tumbling Today – Motley Fool” on October 25, 2018, also Fool.com with their article: “5 Key Takeaways From NovoCure’s Big First Quarter – Motley Fool” published on May 07, 2019, Nasdaq.com published: “Notable ETF Inflow Detected – IWM, HAE, NVCR, CHGG – Nasdaq” on July 24, 2019. More interesting news about NovoCure Limited (NASDAQ:NVCR) were released by: Nasdaq.com and their article: “China National Medical Products Administration Grants Innovative Medical Device Designation for OptuneĀ® in China – Nasdaq” published on August 12, 2019 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly’s Nasal Low Blood Sugar Drug – Benzinga” with publication date: July 25, 2019.

NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors. The company has market cap of $8.88 billion. The firm markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It currently has negative earnings. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma.

NovoCure Limited (NASDAQ:NVCR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.